AUTHORS
Mingyang Wang, Jacques-Emmanuel Galimard2, Jurjen Versluis Sr, MD, PhD3, Hélène Labussière-Wallet, MD4, Deborah Desmier5, Regis Peffault De Latour, MD, PhD6, Mahmoud Aljurf, MD7, Vesa Lindström8, Gitte Olesen9, Mieke WH Roeven, MD, PhD10, Patrice Chevallier, MD, PhD11, Arancha Bermúdez, MD12, Yves Chalandon13, Etienne Daguindau14, Anne Huynh, MD15, Virginie Gandemer, MD, PhD16, Peter Von Dem Borne, MD, PhD17, Alexandros Spyridonidis18, Francesco Saraceni, MD19, Frédéric Baron20, Norbert Claude Gorin, MD, PhD21, Yigeng Cao II, MD, PhD22, Erlie Jiang, MD23, Arnon Nagler I, MD24, Fabio Ciceri, MD25, Eolia Brissot, MD, PhD26
AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 EBMT Paris Office, Hôpital Saint-Antoine, AP-HP,, Paris, France
3 Erasmus MC Cancer Institute, Rotterdam, Netherlands
4 Centre Hospitalier Lyon Sud, Pierre Benite cedex, France
5 Hopital La Miletrie, Poitiers, France
6 Saint-Louis Hospital, BMT Unit, Paris, France
7 King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
8 Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland
9 Aarhus University Hospital | Denmark, Aarhus, Denmark
10 Nijmegen Medical Centre, Nijmegen, Netherlands
11 CHU Nantes, Nantes, France
12 Hospital U. Marques de Valdecilla, Santander, Spain
13 Departement d'Oncologie, Service d'Hematologie, Geneva, Switzerland
14 CHU Besancon Franche-Comte, Besancon, France
15 CHU - Institut Universitaire du Cancer Toulouse, Toulouse, France
16 Centre Hospitalier Universitaire de Rennes, Rennes, France
17 Leiden University Hospital, Leiden, Netherlands
18 Research Committee - University of Patras, Patras, Greece
19 Azienda Ospedali Riuniti di Ancona, Ancona, Italy
20 University of Liege, Liege, Belgium
21 Department of Clinical Hematology and Cellular Therapy, Hôpital Saint-Antoine, AP-HP, Paris, France
22 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
23 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
24 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
25 Unit of Hematology and Stem Cell Transplantation, Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
26 Department of Clinical Hematology and Cellular Therapy, Hôpital Saint-Antoine, AP-HP, Pairs, France, EBMT Paris Office, Hôpital Saint-Antoine, AP-HP, Paris, France
ABSTRACT
Background
Central nervous system (CNS) involvement in acute myeloid leukemia (AML) is a rare but high-risk disease feature associated with poor outcomes. Allogeneic stem cell transplantation (allo-HCT) represents a potentially curative option. However, the optimal conditioning regimen in this setting remains uncertain. Whether total body irradiation (TBI) conditioning provides superior disease control or survival compared with chemotherapy-based conditioning has not yet been established. Therefore, we analyzed EBMT registry data to compare TBI-based and chemotherapy-based conditioning in patients with AML and CNS involvement at diagnosis, undergoing allo-HCT.
Method
A total of 372 adult patients (≥18 years) with AML and CNS involvement at diagnosis who underwent allo-HCT in first complete remission between 2010 and 2024 were identified. Propensity score matching was performed using a caliper width of 0.2. Matching variables included age at transplant, sex, ELN 2022 cytogenetic risk, year of allo-HCT, interval from diagnosis to allo-HCT, recipient CMV serostatus, donor type, and conditioning intensity.
Results
After propensity score matching, 278 patients were included, with 182 receiving chemotherapy-based conditioning (Chemo group) and 96 receiving TBI-based conditioning (TBI group). Baseline characteristics were well balanced between the 2 groups, including donor age, donor type, and donor-recipient CMV serostatus. In the Chemo and TBI groups, 59.9% and 64.6% of patients, respectively, received myeloablative conditioning. The median follow-up for the entire cohort was 3.9 years (95% CI, 3.1–4.1). No significant differences in survival outcomes were observed between the two groups. The 2-year overall survival (OS) and 2-year leukemia-free survival (LFS) were 70.4% (95% CI, 62.8–76.7) and 63.6% (95% CI, 55.8–70.3), respectively, in the Chemo group, versus 61.5% (95% CI, 50.1–70.9) and 57.3% (95% CI, 46.2–67.0) in the TBI group (HR: 1.14, P=0.50 for OS; HR:1.03, P=0.85 for LFS). Likewise, the 2-year cumulative incidence of relapse (CIR) was not different between the Chemo and TBI groups (23.7% [95% CI, 17.6–30.3] vs. 26.4% [95% CI, 17.8–35.9]; HR 0.99, P=0.99), nor did non-relapse mortality (NRM: 12.7% [95% CI, 8.3–18.2] vs. 16.2% [95% CI, 9.3–24.9]; HR 1.10, P=0.75). The cumulative incidence of chronic GVHD was significantly higher in the TBI group than the Chemo group (43.6% [95% CI, 32.4–54.1] vs. 32.9% [95% CI, 25.4–40.6]; HR, 1.69; P=0.02). However, no significant differences were observed in the incidence of moderate/severe/extensive chronic GVHD or acute GVHD between the 2 groups.
Conclusion
Among patients with AML and CNS involvement at diagnosis undergoing allo-HCT in CR1, TBI-based conditioning was not associated with any significant differences in OS, LFS, CRI, and NRM compared with chemotherapy- based conditioning, but with a higher incidence of chronic GVHD. These findings suggest that TBI-based conditioning does not confer a survival advantage over chemotherapy-based conditioning in this setting.
DISCLOSURES
Mingyang Wang: No relevant conflicts of interest to declare.